62 results
8-K
EX-99.1
TLPH
Talphera Inc.
6 Mar 24
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
pancreatitis or as an anti-viral treatment, amongst other potential targets.
About the NEPHRO CRRT Study
The NEPHRO Study, which recently received central
8-K
EX-99.1
TLPH
Talphera Inc.
1 Mar 24
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
7:35am
), disseminated intravascular coagulation (DIC), acute pancreatitis and as an antiviral, amongst other potential targets.
Forward-looking statements
This press
8-K
EX-99.1
TLPH
Talphera Inc.
22 Jan 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
5:12pm
other potential targets.
Forward-looking statements
This press release contains forward-looking statements based upon Talphera's current expectations
8-K
EX-10.1
pc4nx30ps
10 Oct 23
Departure of Directors or Certain Officers
4:17pm
8-K
EX-99.2
z8ew7ehzl41g2zlqlr
31 Jul 23
Other Events
9:47pm
8-K
EX-99.1
pqn8548ehxopgjfb4o3
31 Jul 23
Other Events
9:47pm
8-K
gn3bh
12 Jan 22
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
4:01pm
8-K
EX-10.1
7w4utao
17 Jun 21
Departure of Directors or Certain Officers
5:11pm